Clinical Trials
3 trialsNCT06064500 2025-03-10
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
Amgen
Approved for marketing
NCT04504513 2021-03-19
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
G1 Therapeutics, Inc.
Approved for marketing
NCT04291937 2020-06-19
A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA
Jazz Pharmaceuticals
Approved for marketing